NYSE:NVOPharmaceuticals
Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus
Novo Nordisk (NYSE:NVO) has launched a multi month subscription program for its obesity drug Wegovy.
The program targets self pay patients, aiming to provide more predictable pricing and potential annual savings.
The initiative includes a distribution partnership with telehealth platform LifeMD and a tiered pricing structure.
Novo Nordisk, known for its diabetes and obesity treatments, is expanding how patients access Wegovy as demand for weight management therapies remains high. By pairing...